<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[클로넬테라퓨틱스 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=49834></link><description><![CDATA[클로넬테라퓨틱스 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 15 Apr 2026 06:23:50 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2025/12/12_990577198_20251229103032_3910037685.png]]></url></image><language>ko-KR</language><item><title><![CDATA[Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1026467</link><description><![CDATA[YONGIN, South Korea--(Business Wire/Korea Newswire)--Clonell Therapeutics, Inc. , a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world‘s first ’Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)‘ therapy platform based on Somatic Cell Nuclear Trans...]]></description><pubDate>Tue, 06 Jan 2026 09:12:07 +0900</pubDate></item></channel></rss>